Endocrinology, Diabetes & Metabolism Doctors in Chestnut Hill, MA Accepting Medicare

3 Endocrinology, Diabetes & Metabolism doctors found. Showing 1 - 3

Marcy A. Cheifetz, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 291 Independence Dr Fl 9, Chestnut Hill, MA 02467 Phone: 617-541-6675    Fax: 617-541-7505

Susan Haden, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 200 Boylston St Ste 301, Chestnut Hill, MA 02467 Phone: 177-313-4006    Fax: 617-566-2224

James A Goldman, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 291 Independence Dr, Chestnut Hill, MA 02467 Phone: 617-541-6675    Fax: 617-541-7505

News Archive

Taking lessons in molecular therapeutics from earthworms to combat COVID

Scientists were interested in further investigating the defense mechanism of earthworms in an effort to discover therapeutic solutions against SARS-CoV-2.

Parents can play a key role in decreasing their child's chances to bully others

With all of the media attention on young people being tormented by bullies and cyberbullies, parents may wonder what they can do to protect their children. The question they may want to ask instead is how can they prevent their child from becoming a bully.

Nuvo receives BfArM positive opinion for Pliaglis

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it has received notice of a positive opinion from the European Decentralized Procedure for the approval of Pliaglis from the German Federal Institute for Drugs and Medical Devices (BfArM), the reference member state.

Kinex Pharmaceuticals doses first actinic keratosis patient with KX2-391 ointment

Kinex Pharmaceuticals announced today that the first actinic keratosis patient has been dosed with KX2-391 ointment in Austin, Texas.

Sanofi's insulin glargine delays progression from pre-diabetes to T2DM

Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer.

Read more Medical News

› Verified 5 days ago